Suppressive Effect of α -mangostin for Cancer Stem Cells in Colorectal Cancer via the Notch Pathway

Min Kyoung Jo

Ewha Womans University

Chang Mo Moon (✉ mooncm27@ewha.ac.kr)

Ewha Womans University

Eun Ju Kim

Ewha Womans University

Jee Hee Kwan

Yonsei University College of Medicine

Xiang Fei

Gachon University

Seong-Eun Kim

Ewha Womans University

Sung-Ae Jung

Ewha Womans University

Minsuk Kim

Ewha Womans University

Yeung-Chul Mun

Ewha Womans University

Young-Ho Anh

Ewha Womans University

Seung-Yong Seo

Gachon University

Tae Il Kim

Yonsei University College of Medicine

Research Article

Keywords: cancer stem cell, colorectal cancer, Notch signal, phytochemical agent, α -mangostin

Posted Date: September 27th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-742929/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Cancer on March 29th, 2022. See the published version at <https://doi.org/10.1186/s12885-022-09414-6>.

Abstract

Background: Since colon cancer stem cells (CSCs) play an important role in chemoresistance and in tumor recurrence and metastasis, targeting of CSCs has emerged as a sophisticated strategy for cancer therapy. α -mangostin (α M) has been confirmed to have antiproliferative and apoptotic effects on cancer cells. This study aimed to evaluate the selective inhibition of α M on CSCs in colorectal cancer (CRC) and the suppressive effect on 5-fluorouracil (5-FU)-induced CSCs.

Methods: The cell viability assay was performed to determine the optimal concentration of α M. A sphere forming assay and flow cytometry with CSC markers were carried out to evaluate the α M-mediated inhibition of CSCs. Western blot analysis and quantitative real-time PCR were performed to investigate the effects of α M on the Notch signaling pathway and colon CSCs. The *in vivo* anticancer efficacy of α M in combination with 5-FU was investigated using a xenograft mouse model.

Results: α M inhibited the cell viability and reduced the number of spheres in HT29 and SW620 cells. α M treatment decreased CSCs and suppressed the 5-FU-induced increase in CSCs on flow cytometry. α M markedly suppressed Notch1, NICD1, and Hes1 in the Notch signaling pathway in a time- and dose-dependent manner. Moreover, α M attenuated CSC markers CD44 and CD133, in a manner similar to that upon DAPT treatment, in HT29 cells. In xenograft mice, the tumor and CSC markers were suppressed in the α M group and in the α M group with 5-FU treatment.

Conclusion: This study shows that low-dose α M inhibits CSCs in CRC and suppresses 5-FU-induced augmentation of CSCs via the Notch signaling pathway.

Background

CRC is the second-most frequent cause of cancer-related deaths in United States and many other high-income countries [1, 2]. While the best way to treat CRC is the complete surgical resection of the primary lesion, less than 25% of all patients are operable, and high percentage of patients may experience recurrence [3–6]. Patients with inoperable CRCs are usually treated with palliative chemotherapy, and a large number of patients have also required postsurgical chemotherapy for preventing tumor recurrence [7].

CSCs are small subset of the cancer cells with characteristics including proliferation, self-renewal, and asymmetric differentiation [8–10]. Conventional chemotherapeutic agents and radiotherapy may show therapeutic effects on rapidly growing tumors but cannot inhibit CSCs [11]. Previous studies reported that conventional chemotherapy can lead to an increase in colorectal CSCs [12, 13]. CSCs are closely associated with chemoresistance, cancer metastasis, and recurrence after primary therapy [8, 14–16]. Therefore, targeting of CSCs has emerged as an important aspect of effective cancer treatment.

Recently, certain components from fruit and vegetables were identified to have a chemopreventive effect on cancers and anticancer properties [17]. Among them, mangostin (*Garcinia mangostana*), a tropical

evergreen tree commonly found in Southeast Asia [18–21], has been used in the traditional treatment of skin infections and in wound-healing for a long time [22]. Among the various secondary metabolites of mangostin, xanthenes and polyphenolic substances show a variety of physiological activities including anti-inflammatory, antibacterial, and anticancer effects [23]. α -mangostin (α M) is one of the main bioactive and most abundant xanthenes extracted from mangostin [23]. To date, α M has been widely investigated as a chemotherapeutic and chemopreventive bioactive compound [24]. In addition, novel xanthone derivatives based on α M were synthesized and evaluated as anticancer agents [25]. Consequently, α M has been shown to be effective in various cancers, including CRC, pancreatic, prostate, oral squamous, and breast cancers [18, 20, 21, 26–29]. In this study, we aimed to evaluate whether α M can selectively inhibit CSCs in CRC and whether it can also suppress an increase in the number of CSCs in combination with conventional anticancer agents.

Methods

Material

5-FU, dimethyl sulfoxide (DMSO), and N-[N-(3,5-difluorophenacetyl)-L-alanyl]-L-phenylglycine-t-butyl ester (DAPT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). α M was provided by professor SY Seo (College of Pharmacy, Gachon University, Republic of Korea) (Figure 1A). 5-FU and α M were dissolved in DMSO. The following antibodies were used for Western blotting and flow cytometry: anti- β -actin (1:1000, Gene Tex, Irvine, USA), anti-HES1 (1:1500, Cell Signaling, Danvers, MA, USA), anti-Notch1, anti-NICD 1 (1:100, Santa Cruz, TX, USA), anti-Hey1 (1:500, abcam, Cambridge, UK), fluorescein (FITC)-conjugated anti-CD44 (1:20, BD bioscience, Franklin Lakes, NJ), and phycoerythrin (PE)-conjugated anti-CD133 (1:50, Miltenyi Biotec, Bergisch Gladbach, Germany).

Cell culture

Human colon cancer cell lines SW620 and HT29 were purchased from Korea Cell Line Bank (Seoul, Republic of Korea). Cells were cultured in Dulbecco's modified Eagle medium (DMEM, Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, MP Biomedicals, France) and 1% antibiotic antimycotic solution (10,000units/ml penicillin and 10 mg/ml streptomycin, Welgene, Daegu, Republic of Korea) in plastic tissue culture flasks under 37°C, 5% CO₂, and 95% humidity.

Cell viability assay

Cell viability was measured by using Cell Counting Kit-8 (CCK-8, Enzo Life Sciences, Farmingdale, NY, USA). Cells were seeded in a 96-well plate (1×10^4 cells/well, 200 μ l/well, SPL, Republic of Korea) in an increasing gradient. SW620 cells were treated with 0, 2.5, 5, 10, 20, and 40 μ M α M for 72 h, and HT29 cells were treated with 0, 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 μ M α M. In each well, the medium was removed, and

90µl plus 10µl CCK-8 solution was added. Thereafter, the plate was incubated for 1h at 37°C. Absorbance was measured at 450 nm on a 96-well microplate reader (Spectra Max M5, MD, USA).

Colosphere forming assay

SW620 and HT29 cells (1000 cells/well) were seeded in 24-well ultralow adherence plates (Corning, NY, USA) in 1ml of CSC media, DMEM/F12 supplemented with B27 (Gibco, Invitrogen, Carlsbad, CA, USA), 2mM L-glutamine (Hyclone), 10ng/µl bFGF (Prospec, East Brunswick, NJ, USA), 20ng/µl EGF (Prospec), and 1% antibiotic antimycotic solution (10,000 units/ml penicillin and 10mg/ml streptomycin, Welgene). Cells were cultured for 14d, and CSC medium was changed every 72h. SW620 cells were treated with 0, 1.25, 2.5µM αM, and HT29 cells were treated with 0, 1.25, 2.5µM αM during the sphere forming assay. The spheres were examined using a microscope at 14 d (Zeiss Axiophot, Carl Zeiss Microscopy LLC, Thornwood, NY, USA). Quantitative real-time PCR and Western blot analyses were conducted with these cells.

3D spheroid invasion assay

The 3D spheroid invasion assay was conducted with the aforementioned HT29 cells. HT29 cells were trypsinized, and 1×10^5 cells were resuspended in 5mL DMEM with 20% methocel solution (methylcellulose, Sigma-Aldrich) and 1% Matrigel (Corning). Hanging drops (25µl) were suspended on petri dishes (SPL), and cells were harvested after 2d. Harvested spheroid cells were embedded in collagen gels (rat tail collagen, BD bioscience), which were polymerized at 37°C. These spheroids were incubated for 5d, and invasion ratios were calculated using ImageJ software (version 1.51J8; National Institutes of Health, Bethesda, MD, USA).

Quantitative real-time PCR analysis

Total cellular RNA was extracted from HT29 cells by using Trizol reagent (Invitrogen) and the RNeasy Mini Kit (Invitrogen) in accordance with the manufacturer's protocol. The total RNA concentration was measured using a Nanodrop spectrophotometer (Nabi UV/Vis Nano spectrophotometer, Microdigital, Gyeonggi, Republic of Korea) with an $A_{260/280}$ cut-off of approximately 2.0. Purified RNA (2µg) was reverse-transcribed (with the Reverse Transcription Kit, Applied Biosystems, Framingham, MA, USA). Quantitative real-time PCR was performed with power SYBR Green master mix (Applied Biosystems) on Quant studio 3. The cycling conditions were as follows: denaturation for 2min at 50°C, 10min at 95°C, followed by 40 cycles at 95°C for 5 s and 60°C for 60s, followed by dissociation for 15s at 95°C and annealing and extension at 60°C for 20 s. The relative mRNA levels were normalized to those of β-actin mRNA using the $2^{-\Delta\Delta C_t}$ method. Primers for quantitative real-time PCR are listed in Supplementary Table 1.

Western blot assay

The Western blot assay was conducted to determine the expression levels of Notch1, NICD1, Hes1, Hey1, and β -actin, under 4 experimental conditions. Proteins were extracted from cells by using radioimmunoprecipitation assay (RIPA) lysis buffer (iNtRON Biotechnology, Gyeonggi, Republic of Korea). The concentration of the isolated proteins was determined using a bicinchoninic acid (BCA) protein assay (Thermo Scientific-Pierce, Waltham, MA, USA). Proteins (20 μ g) were separated through 8%, 10%, and 12% SDS-PAGE (Hoefer, San Francisco, CA, USA) and transferred to polyvinylidene fluoride membranes (PVDF, Merck). The membranes were blocked using 3% bovine serum albumin (BSA, Sigma-Aldrich) for 30min at room temperature (RT). Protein extracts were incubated with primary antibodies overnight at 4°C and with secondary antibodies for 1h at RT. Proteins were detected using the enhanced chemiluminescence (ECL) Western blotting Luminol reagent (Santa Cruz). Images were obtained using a Lumino image analyzer (LAS-4000 Mini, Fujifilm, Tokyo, Japan).

Flow cytometry

For flow cytometry, cells were washed with PBS and incubated with Accutase (Gibco) for 10 min. After adding flow cytometry buffer (2.5g BSA [Sigma-Aldrich] and 0.372g EDTA [Sigma-Aldrich] in 500ml PBS [Biosesang, Seongnam, Republic of Korea]), cells were incubated with primary antibodies at 4°C in the dark for 45min. CD133 was conjugated with PE and CD44 was conjugated with FITC for labeling cells. Labeled cells were resuspended in flow cytometry buffer. All samples were analyzed using the Novo-Cyte flow cytometer (ACEA Biosciences, San Diego, CA, USA).

Assessment of *in vivo* anticancer efficacy

Six-week-old male Balb/c athymic mice were purchased from Orient Bio (Seongnam, Republic of Korea) and acclimated for 1 week. All mouse experiments were conducted under approved guidelines of the Animal Care and Use Committee of Ewha Womans University (EUM17-0368). HT29 cells (1×10^6 cells) were suspended in DMEM with Matrigel matrix (1:1 ratio). The mixed cells were injected subcutaneously into the right rear flank of each mouse. After 11 days of injection, mice were divided into 4 treatment-based groups (5 mice per group): control, 5-FU only, α M only, and 5-FU and α M. 5-FU (30 mg/kg body weight) or/and α M (5 mg/kg) were administered intraperitoneally thrice a week for 18 d. Tumor volume was calculated (volume = length $\times$ width $\times$ width/2), and body weight was measured thrice a week. All mice were euthanized through CO₂ asphyxiation, and the weight and volume of the excised tumor were measured on day 29.

Statistical analysis

Data are expressed as mean $\pm$ standard error of the mean (SEM) or mean $\pm$ standard deviation (SD) values. All analyses were performed using Graph Pad Prism 8.0 software (Graph Pad Software, La Jolla, CA, USA) and SPSS software (version 22.0, Chicago, IL, USA). A *P* value of <0.05 was considered significant. Statistical significance was determined using the Mann–Whitney *U* test for nonparametric data and a two-tailed Student *t* test for parametric data.

Results

Cell viability assay of α M-treated colon cancer cells

Cell viability assays were performed to determine the minimum dose of α M, which can inhibit CSCs without obvious cytotoxicity. The cell viability of SW620 was 100% upon treatment with 0, 2.5, and 5 μ M α M, 94.01% with 10 μ M α M, 11.27% with 20 μ M α M, and 5.73% with 40 μ M α M ($P < 0.001$) (Fig. 1B). In HT29 cells, the cell viability was almost 100% upon treatment with 0–2.0 μ M α M, and 84.16% with 4 μ M α M ($P < 0.05$), and 66.26% with 8 μ M α M ($P < 0.05$) (Fig. 1C). These results suggest that the optimal concentration of α M was less than 5 μ M in SW620 cells and less than 2 μ M in HT29 cells for further *in vitro* assays.

Inhibitory effect of low-dose α M on colosphere formation

The number of spheres from SW620 cells decreased after the treatment with α M in a dose-dependent manner (Fig. 1D). Compared to the control group, 1.25 μ M ($P < 0.01$) and 2.5 μ M ($P < 0.001$) α M significantly decreased sphere formation in SW620 cells. In HT29 cells, the number of spheres were significantly decreased upon treatment with 0.25 μ M ($P < 0.001$) and 0.5 μ M ($P < 0.001$) α M (Fig. 1E). These results indicate that sphere formation was suppressed with low-dose α M in both SW620 and HT29 cells.

Reduction of CSCs and 5-FU–induced CSCs upon treatment with low-dose α M

To evaluate the inhibitory effect of α M on CSCs and 5-FU–induced increase in CSCs, the expression levels of CD133 and CD44, which are well-known as CSC markers, were monitored after treating HT29 cells with α M with or without 5-FU for 72 h (Fig. 2A). The proportion of CD133⁺CD44⁺ cells significantly decreased upon treatment with 0.5 μ M (control: 31.48% vs α M: 25.86%; $P < 0.01$) and 1.0 μ M α M (control: 31.48% vs α M: 23.94%; $P < 0.001$). The proportion of CD133⁺CD44⁺ cells increased to 56.72% upon treatment with 2 μ M 5-FU and decreased to 46.89% or 40.23% upon treatment with 0.5 μ M or 1.0 μ M of α M, respectively. These results suggest that α M selectively inhibits CSCs and the 5-FU–induced increase in CSCs. In addition, a 3D spheroid invasion assay was conducted to analyze the effect of α M on cancer cell

invasion. As shown in Fig. 2B, αM significantly inhibited cancer cell invasion compared to the control (54.77% vs 100%, respectively; $P < 0.05$).

Inhibition of CSCs via the NOTCH-HES1 pathway Upon treatment with low-dose αM

Notch signaling, a highly conserved pathway, is reportedly involved in the self-renewal of CSCs and contributes to cancer metastasis (Gu et al, 2012; Pannuti et al, 2010)[30, 31]. In colospheres of HT29 cells, treatment with 0.25 and 0.50 μM αM downregulated Notch1, Hes1, and Hey1 (Fig. 3A) and significantly attenuated Hes1 mRNA levels (Fig. 3B). Notch signaling proteins including Notch1, Hes1, and Hey1 were downregulated after αM treatment in HT29 cells (Fig. 3C). Furthermore, mRNA levels of Notch1, Hes1, and Hey1 were decreased upon treatment with αM, which was similar to the inhibitory effect of a γ-secretase inhibitor, DAPT (Fig. 3D). As shown in Fig. 3E, the proportion CD133⁺CD44⁺ cells significantly decreased upon treatment with both αM (control: 25.26% vs 1.0 μM αM: 15.24%; $P = 0.0083$) and DAPT (control: 25.26% vs 20 μM DAPT: 15.36%; $P = 0.0019$). In addition, the 5-FU–induced increase in CD133⁺CD44⁺ cells were significantly attenuated upon treatment with αM (5-FU: 69.35% vs 5-FU + αM: 59.81%; $P = 0.0473$) and DAPT (5-FU: 69.35% vs 5-FU + DAPT: 57.36%; $P = 0.0281$). These results suggest that Notch signaling is related to the CSC-suppressive effect of αM.

CSC-inhibitory effect on αM in an in vivo xenograft mouse model

To evaluate the inhibitory effect of αM on CRC CSCs *in vivo*, its antitumor efficacy was assessed using a xenograft mouse model. 5-FU and/or αM were administered intraperitoneally to mice from days 11–28 (Fig. 4A). Among 4 groups including the control, 5-FU only, αM only, and 5-FU + αM, no significant differences were observed in body weight (Fig. 4B). Regarding tumor volume, tumors in the 5-FU + αM group were significantly smaller than those in the 5-FU only treatment group, and tumors in the αM group were significantly smaller than those in the control group (Fig. 4C). On day 29, the weight of the excised tumor of the 5-FU + αM group was significantly lower than that in the 5-FU only group (5-FU: 0.3 g vs 5-FU + αM: 0.14 g; $P < 0.01$), while no difference was observed between the control and αM only groups (Fig. 4D).

Regarding the CSC population in the excised tumors, treatment with αM only decreased the proportion of CD133⁺CD44⁺ cells compared to control (17.74% vs 11.72%, respectively; $P < 0.01$), and 5-FU + αM treatment attenuated these cells compared to the 5-FU only group (13.35 vs 8.39%, respectively; $P < 0.001$). Overall, our results show that αM not only inhibits CSCs but also exerts synergistic therapeutic effects in combination with 5-FU.

Discussion

This study shows that αM has an inhibitory effect on CRC CSCs and attenuates a 5-FU–induced increase in CSCs [32]. The effects of αM on apoptosis and cell cycle arrest through several signaling pathways in CRC have been widely studied [19, 33–36]. Several studies have reported that αM arrests the cell cycle by regulating cyclins and p27 in DLD-1 cells [33–35]. Furthermore, αM induces apoptosis through the extrinsic and intrinsic pathways in COLO 205 cells [33, 36]. Moreover, αM induces apoptosis via the mitochondrial signaling pathway, which is regulated by MAPK, ERK, and Akt [19, 34]. In particular, apoptotic signals induced by the expression of proapoptotic proteins p21 and Bax owing to ERK activation, are relevant to the NF-κB pathway [19, 34].

Furthermore, αM is reported to have potential anticancer and antiproliferative effects on cervical and pancreatic CSCs [37, 38]. αM can inhibit CSC-like spheroids in human breast cancer cells, resulting in a significant reduction in the adherence and migration of cancer cells [39]. Combinatorial treatment with αM and cisplatin reportedly enhanced the therapeutic effects of cisplatin on cervical cancer and attenuated the chemoresistance of cancer cells to cisplatin by inducing apoptosis in CSC-like cervical cancer cells [37]. Combinatorial treatment with αM and doxorubicin reduces cell viability and decreases the retinaldehyde-dependent isoenzymes of aldehyde dehydrogenase (RALDH), a CSC marker, in spheroids of human breast cancer cell line MCF-7 [40]. Combinatorial treatment with αM and chemotherapeutic agents can help overcome chemoresistance through the suppression of CSCs.

The Notch signaling pathway, a highly conserved cellular signaling pathway, plays an important role in proliferation, stem cell maintenance, cell fate specification, differentiation, and homeostasis in multicellular organisms [41–43]. Some studies have reported that the Notch signaling is one of the most critical pathways in cancer metastasis [44]. Notch signaling can induce colon adenoma together with Wnt signaling and is necessary to eradicate drug-resistant CRC CSCs [45, 46]. Notch1 expression is dysregulated in the initiation step of CRC [47–49], positively predicts poor overall survival [50], and is upregulated in advanced tumors [51]. The inhibition of this pathway may enhance therapeutic efficacy in the curative treatment of cancer by eradicating CSCs [44, 52].

We hypothesized that αM selectively suppresses CSCs in CRC, and the combined use of αM and current anticancer agents including 5-FU exerts synergistic effects on CRC. The CSC-inhibitory effect was observed upon treatment with low-dose αM without concerns of cytotoxicity. Our results show the differences in αM concentrations and the sphere forming ability between the HT29 and SW620 cells. It should be noted that these differences originated from the different properties of each cell line. HT29 cells derived from primary cancer and SW620 cells were derived from lymph node metastasis. Further, HT29 cells harbored V600E BRAF, P449T PIK3CA, R273H, and TP53 mutations, whereas SW620 cells harbored G12V KRAS, R273H, P309S, and TP53 mutations [53]. Even though both were CRC cell lines, the differences in experimental conditions were inevitable owing to intrinsic properties. In both HT29 spheres and the cell line, Notch, Hes1, and Hey1 were downregulated after αM treatment. In addition, the CSC proportion decreased upon treatment with both αM and DAPT. Of note, the mechanism underlying the CSC-inhibitory effects of αM in CRC are associated with Notch signaling. Moreover, the attenuation of the

5-FU–induced increase in CSCs by αM suggests that αM has the potential to suppress chemoresistance in CSCs.

Conclusions

In conclusion, our results show that αM suppresses CSCs and inhibits the 5-FU–induced increase in CRC CSCs via Notch signaling. In particular, the fact that therapeutic efficacy is improved only with low-dose αM provides a strong advantage for clinical use. αM might be a promising adjunctive agent with conventional anticancer agents to improve treatment efficacy among patients with CRC.

Abbreviations

CRC, colorectal cancer; CSC, cancer stem cell; 5-FU, Fluorouracil; DMEM, Dulbecco's modified Eagle medium; FBS, Fetal Bovine Serum; DMSO, dimethyl sulfoxide; Hes1, hairy and enhancer of split; Hey1, Hes related with YRPW motif 1; FITC, fluorescein; PE, phycoerythrin; CCK-8, Cell Counting Kit-8; PVDF, Polyvinylidene fluoride membranes; RT, Room temperature; 3D, Three dimension; ECL, Enhanced chemiluminescence; RIPA, Radioimmunoprecipitation assay; BSA, bovine serum albumin; BCA, Bicinchoninic acid

Declarations

Availability of data and materials

All the data generated or analyzed during this study are included in this published article.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2020R1A2C1010786 and 2020R1A5A2019210; Chang Mo Moon).

Authors' contributions

Chang Mo Moon and Seung-Yong Seo directed, and Tae Il Kim and Chang Mo Moon initiated the project. Min Kyoung Jo and Eun Ju Kim and Jee Hee Kwan and Xiang Fei performed the experiments. Min

Kyoung Jo and Chang Mo Moon wrote the manuscript. Min Kyoung Jo and Chang Mo Moon and Young-Ho Anh participated in editing the manuscript. Seong-Eun Kim and Sung-Ae Jung and Minsuk Kim and Young Cheol Moon and Young-Ho Anh and Seung-Yong Seo and Tae Il Kim made critical revisions. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved and conducted according to regulations and guidelines of the Ewha Womans University College of Medicine Institutional Animal Care and Use Committee (EUM17-0368): Reporting In vivo Experiments (ARRIVE) guidelines. All procedures were in accordance with the Guide and Regulate by Ewha Womans University.

Consent for publication

The authors have no conflicts to disclose.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, 07985, Republic of Korea ²Inflammation-Cancer Microenvironment Research Center, College of Medicine, Ewha Womans University, Seoul, 07804, Republic of Korea ³Department of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul, 07804, Republic of Korea ⁴Department of Internal Medicine, Yonsei University College of Medicine, 03722, Seoul, Republic of Korea ⁵Department of Pharmacy, Gachon University, Kyounggi, 21936, Republic of Korea ⁶Department of Pharmacology, College of Medicine, Ewha Womans University, Seoul, 07804, Republic of Korea

References

1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A: **Colorectal cancer statistics, 2020**. *CA Cancer J Clin* 2020, **70**(3):145–164.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F: **Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012**. *European Journal of Cancer* 2013, **49**(6):1374–1403.

3. Obrand DI, Gordon PH: **Incidence and patterns of recurrence following curative resection for colorectal carcinoma.** *Diseases of the Colon & Rectum* 1997, **40**(1):15–24.
4. Faerden AE, Naimy N, Wiik P, Reiertsen O, Weyessa S, Trønnes S, Andersen SN, Bakka A: **Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer.** *Dis Colon Rectum* 2005, **48**(12):2224–2231.
5. Huh JW, Park YA, Lee KY, Kim SA, Sohn S-K: **Recurrences after Local Excision for Early Rectal Adenocarcinoma.** *Yonsei Med J* 2009, **50**(5):704–708.
6. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C: **Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.** *BMC Cancer* 2010, **10**:134.
7. **Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis.** *BMJ* 2000, **321**(7260):531.
8. Chan KS: **Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation.** *Clin Cancer Res* 2016, **22**(4):802–806.
9. de Sousa e Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z, Koeppen H *et al*: **A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer.** *Nature* 2017, **543**(7647):676–680.
10. Bu Y, Cao D: **The origin of cancer stem cells.** *Front Biosci (Schol Ed)* 2012, **4**:819–830.
11. Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q, Lin J, Tan S, Tian Y, Liao Q *et al*: **Cancer stem cells in progression of colorectal cancer.** *Oncotarget* 2018, **9**(70):33403–33415.
12. Reya T, Morrison SJ, Clarke MF, Weissman IL: **Stem cells, cancer, and cancer stem cells.** *Nature* 2001, **414**(6859):105–111.
13. Zhou BBS, Zhang HY, Damelin M, Geles KG, Grindley JC, Dirks PB: **Tumour-initiating cells: challenges and opportunities for anticancer drug discovery.** *Nature Reviews Drug Discovery* 2009, **8**(10):806–823.
14. Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A, Sgambato A: **Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.** *World J Gastroenterol* 2014, **20**(4):923–942.
15. Shiozawa Y, Nie B, Pienta KJ, Morgan TM, Taichman RS: **Cancer stem cells and their role in metastasis.** *Pharmacol Ther* 2013, **138**(2):285–293.
16. Shen Y, Cao D: **Hepatocellular carcinoma stem cells: origins and roles in hepatocarcinogenesis and disease progression.** *Front Biosci (Elite Ed)* 2012, **4**:1157–1169.
17. Oh J, Hlatky L, Jeong YS, Kim D: **Therapeutic Effectiveness of Anticancer Phytochemicals on Cancer Stem Cells.** *Toxins (Basel)* 2016, **8**(7).
18. Hafeez BB, Mustafa A, Fischer JW, Singh A, Zhong W, Shekhani MO, Meske L, Havighurst T, Kim K, Verma AK: **alpha-Mangostin: a dietary antioxidant derived from the pericarp of *Garcinia mangostana* L. inhibits pancreatic tumor growth in xenograft mouse model.** *Antioxid Redox Signal* 2014, **21**(5):682–699.

19. Aisha AF, Abu-Salah KM, Ismail Z, Majid AM: **In vitro and in vivo anti-colon cancer effects of *Garcinia mangostana* xanthones extract.** *BMC Complement Altern Med* 2012, **12**:104.
20. Chitchumroonchokchai C, Thomas-Ahner JM, Li J, Riedl KM, Nontakham J, Suksumrarn S, Clinton SK, Kinghorn AD, Failla ML: **Anti-tumorigenicity of dietary alpha-mangostin in an HT-29 colon cell xenograft model and the tissue distribution of xanthones and their phase II metabolites.** *Mol Nutr Food Res* 2013, **57**(2):203–211.
21. Wang JJ, Shi QH, Zhang W, Sanderson BJ: **Anti-skin cancer properties of phenolic-rich extract from the pericarp of mangosteen (*Garcinia mangostana* Linn.).** *Food Chem Toxicol* 2012, **50**(9):3004–3013.
22. Wexler B: **Mangosteen.** *Salt Lake City, UT: Woodland Publishing* 2007.
23. Obolskiy D, Pischel I, Siriwatanametanon N, Heinrich M: ***Garcinia mangostana* L.: a phytochemical and pharmacological review.** *Phytother Res* 2009, **23**(8):1047–1065.
24. Shan T, Ma Q, Guo K, Liu J, Li W, Wang F, Wu E: **Xanthones from mangosteen extracts as natural chemopreventive agents: potential anticancer drugs.** *Curr Mol Med* 2011, **11**(8):666–677.
25. Fei X, Jo M, Lee B, Han SB, Lee K, Jung JK, Seo SY, Kwak YS: **Synthesis of xanthone derivatives based on alpha-mangostin and their biological evaluation for anti-cancer agents.** *Bioorg Med Chem Lett* 2014, **24**(9):2062–2065.
26. Li P, Tian W, Ma X: **Alpha-mangostin inhibits intracellular fatty acid synthase and induces apoptosis in breast cancer cells.** *Mol Cancer* 2014, **13**:138.
27. Kwak HH, Kim IR, Kim HJ, Park BS, Yu SB: **alpha-Mangostin Induces Apoptosis and Cell Cycle Arrest in Oral Squamous Cell Carcinoma Cell.** *Evid Based Complement Alternat Med* 2016, **2016**:5352412.
28. Kurose H, Shibata MA, Iinuma M, Otsuki Y: **Alterations in cell cycle and induction of apoptotic cell death in breast cancer cells treated with alpha-mangostin extracted from mangosteen pericarp.** *J Biomed Biotechnol* 2012, **2012**:672428.
29. Johnson JJ, Petiwala SM, Syed DN, Rasmussen JT, Adhami VM, Siddiqui IA, Kohl AM, Mukhtar H: **alpha-Mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth.** *Carcinogenesis* 2012, **33**(2):413–419.
30. Gu JW, Rizzo P, Pannuti A, Golde T, Osborne B, Miele L: **Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy.** *Vasc Cell* 2012, **4**:7.
31. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L: **Targeting Notch to target cancer stem cells.** *Clin Cancer Res* 2010, **16**(12):3141–3152.
32. Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F *et al*: **Targeting cancer stem cell pathways for cancer therapy.** *Signal Transduct Target Ther* 2020, **5**(1):8.
33. Watanapokasin R, Jarinthanan F, Nakamura Y, Sawasjirakij N, Jaratrungtawee A, Suksamrarn S: **Effects of alpha-mangostin on apoptosis induction of human colon cancer.** *World J Gastroenterol* 2011, **17**(16):2086–2095.

34. Akao Y, Nakagawa Y, Iinuma M, Nozawa Y: **Anti-cancer effects of xanthones from pericarps of mangosteen.** *Int J Mol Sci* 2008, **9**(3):355–370.
35. Matsumoto K, Akao Y, Ohguchi K, Ito T, Tanaka T, Iinuma M, Nozawa Y: **Xanthones induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells.** *Bioorg Med Chem* 2005, **13**(21):6064–6069.
36. Watanapokasin R, Jarinthanan F, Jerusalmi A, Suksamrarn S, Nakamura Y, Sukseree S, Uthaisang-Tanethpongtham W, Ratananukul P, Sano T: **Potential of xanthones from tropical fruit mangosteen as anti-cancer agents: caspase-dependent apoptosis induction in vitro and in mice.** *Appl Biochem Biotechnol* 2010, **162**(4):1080–1094.
37. Chien HJ, Ying TH, Hsieh SC, Lin CL, Yu YL, Kao SH, Hsieh YH: **alpha-Mangostin attenuates stemness and enhances cisplatin-induced cell death in cervical cancer stem-like cells through induction of mitochondrial-mediated apoptosis.** *J Cell Physiol* 2020, **235**(7–8):5590–5601.
38. Ma Y, Yu W, Shrivastava A, Srivastava RK, Shankar S: **Inhibition of pancreatic cancer stem cell characteristics by alpha-Mangostin: Molecular mechanisms involving Sonic hedgehog and Nanog.** *J Cell Mol Med* 2019, **23**(4):2719–2730.
39. Scolamiero G, Pazzini C, Bonafe F, Guarnieri C, Muscari C: **Effects of alpha-Mangostin on Viability, Growth and Cohesion of Multicellular Spheroids Derived from Human Breast Cancer Cell Lines.** *Int J Med Sci* 2018, **15**(1):23–30.
40. Bissoli I, Muscari C: **Doxorubicin and alpha-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids.** *Biomed Pharmacother* 2020, **124**:109927.
41. Reichrath J, Reichrath S: **Notch Signaling and Embryonic Development: An Ancient Friend, Revisited.** *Adv Exp Med Biol* 2020, **1218**:9–37.
42. Liu J, Sato C, Cerletti M, Wagers A: **Notch signaling in the regulation of stem cell self-renewal and differentiation.** *Curr Top Dev Biol* 2010, **92**:367–409.
43. Sato C, Zhao G, Ilagan MX: **An overview of notch signaling in adult tissue renewal and maintenance.** *Curr Alzheimer Res* 2012, **9**(2):227–240.
44. Venkatesh V, Nataraj R, Thangaraj GS, Karthikeyan M, Gnanasekaran A, Kaginelli SB, Kuppanna G, Kallappa CG, Basalingappa KM: **Targeting Notch signalling pathway of cancer stem cells.** *Stem Cell Investig* 2018, **5**:5.
45. Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernandez-Majada V, Grilli A, Lopez-Bigas N, Bellora N, Alba MM, Torres F *et al.*: **Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer.** *Proc Natl Acad Sci U S A* 2009, **106**(15):6315–6320.
46. Fre S, Pallavi SK, Huyghe M, Lae M, Janssen KP, Robine S, Artavanis-Tsakonas S, Louvard D: **Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine.** *Proc Natl Acad Sci U S A* 2009, **106**(15):6309–6314.
47. Tyagi A, Sharma AK, Damodaran C: **A Review on Notch Signaling and Colorectal Cancer.** *Cells* 2020, **9**(6).

48. Vinson KE, George DC, Fender AW, Bertrand FE, Sigounas G: **The Notch pathway in colorectal cancer.** *Int J Cancer* 2016, **138**(8):1835–1842.
49. Qiao L, Wong BC: **Role of Notch signaling in colorectal cancer.** *Carcinogenesis* 2009, **30**(12):1979–1986.
50. Chu D, Zhang Z, Zhou Y, Wang W, Li Y, Zhang H, Dong G, Zhao Q, Ji G: **Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer.** *Ann Oncol* 2011, **22**(11):2440–2447.
51. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM *et al*: **A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.** *Int J Cancer* 2016, **138**(1):195–205.
52. Huang R, Wang G, Song Y, Tang Q, You Q, Liu Z, Chen Y, Zhang Q, Li J, Muhammand S *et al*: **Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.** *Mol Med Rep* 2015, **12**(2):2417–2424.
53. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE, Lothe RA: **Epigenetic and genetic features of 24 colon cancer cell lines.** *Oncogenesis* 2013, **2**:e71.

Figures

Figure 1

Figure 1

Cell viability assay and colosphere forming assay with α M-treated cancer stem cells. (A) mangostin fruit and chemical structure of α M extracted from *Garcinia mangostana* Linn. (B), (C) Effect of α M on the viability of SW620 and HT29 cells. SW620 and HT29 cells were treated with various concentrations of α M (0, 2.5, 5.0, 10, 20, and 40 μ M in SW620 cells; 0, 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 μ M in HT29 cells) for 72 h. (D), (E) The colosphere forming assay was conducted with various concentrations of α M (0, 1.25, and

2.5μM in SW620 cells; 0, 0.25, and 0.5μM in HT29 cells) for 14 days. Based on a size-matched control for each cell line, the number of spheres in SW620 and HT29 cells were counted on day 14. Data are expressed as mean ± SD values. *p <0.05, **p <0.01, ***p <0.001.

Figure 2

Figure 2

αM decreased CSCs and 5-FU-induced CSCs. (A) HT29 cells were treated with 0, 0.5, and 1.0μM αM and with or without 2μM 5-FU for 72 h. CD44-FITC and CD133-PE double-positive cells were analyzed using

flow cytometry in HT29 cells. αM decreased the proportion of CD44 and CD133 cells relative to the control group, and αM with 5-FU treatment also reduced this proportion relative to 5-FU only. All data indicate dose-dependent effects. Data are expressed as mean ± SEM values. (B) The 3D spheroid invasion assay was conducted to analyze the effect of αM on cancer cell invasion. αM significantly inhibited cancer cell invasion compared to the control group. Data are expressed as mean ± SD values. *p <0.05, **p <0.01, ***p <0.001.

Figure 3

Figure 3

α M inhibited CSCs through the NOTCH-HES1 pathway. (A) Western blot analysis for Notch1, NICD1, Hes1, Hey1, and β -actin with HT29 cells treated with α M at various concentrations. α M downregulated Notch1, NICD1, Hes1, and Hey1 in a concentration-dependent manner. (B) Quantitative real-time PCR analyses showing the mRNA levels of Hes1 in HT29 spheres treated with 0, 0.25, and 0.5 μ M α M for 14 d. Hes1 mRNA was downregulated upon treatment with α M in the sphere forming assay. (C) Western blot showing protein levels of Notch1, NICD1, Hes1, Hey1, and β -actin in HT29 spheres treated with α M at different concentrations. Notch was downregulated upon treatment with 0, 1.0, and 2.0 μ M α M in a concentration-dependent manner. (D) mRNA expression of Notch pathway factors: Notch1, Hes1, and Hey1 expression was quantified in HT29 cells through quantitative real-time PCR. α M downregulated Notch1, Hes1, and Hey1. Data are expressed as mean $\pm$ SD values. (E) Expression of CD44 and CD133 (cancer stem cell markers) was analyzed with or without 5-FU treatment through flow cytometry, using α M or DAPT. HT29 cells were treated with 1.0 μ M α M and DAPT with or without 5-FU for 72 h for 11 times. the proportion of CD133+CD44+ cells was significantly decreased with both α M and DAPT. In addition, the 5-FU-induced increase in CD133+CD44+ cells was significantly attenuated by α M and DAPT treatment. Data are expressed as mean $\pm$ SEM values; * p <0.05, ** p <0.01, *** p <0.001.

Figure 4

Figure 4

α M shows an inhibitory effect on CSCs in an in vivo xenograft mouse model. (A) Schematic representation of the experimental design. (B) Body weight of mice was not significantly different between the control group and the other groups during the experiment (Student's t test). (C) Tumor volume in the HT29 xenograft mice treated with each agent. The tumor volume of the control group was larger than that in the α M group. Tumor volume of the 5-FU + α M group was significantly larger than that

in the 5-FU only group. (D) Tumors from each group were weighed immediately after resection. The tumor weight in the 5-FU + α M group was significantly lower than that in the 5-FU group. (E) CD44/CD133 double-positive tumors in the α M group were significantly fewer than those in the α M group. These proportions were significantly lower in the 5-FU+ α M group than in the 5-FU group. Data are expressed as mean $\pm$ SEM values; *p <0.05, **p <0.01, ***p <0.001.

Figure 5

Schematic illustration of role of aM in regulation of CSCs in CRC cell lines. Low-dose of aM induced suppression of Notch signaling pathway in CRC, leading to a rise in targeting chemo-resistant CSCs.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigure1.tif](#)
- [SupplementaryFigure2.tif](#)
- [SupplementaryFigure3.tif](#)
- [Supplementarytable1.tif](#)